Medtronic Launches MiniMed 780G System, Expanding Choices for Diabetes Patients
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6d ago
0mins
Should l Buy MDT?
Medtronic announced three significant U.S. milestones that expand access, choice, and flexibility for people living with type 1 and insulin-requiring type 2 diabetes. These milestones include Medicare access for the MiniMed 780G system paired with the Instinct sensor, made by Abbott, FDA clearance for the system's use with ultra rapid-acting insulins, and clearance of the MiniMed 780G system for use with the Instinct sensor for insulin-requiring type 2 diabetes. Medicare and Medicare Advantage beneficiaries can now access the MiniMed 780G system with the Instinct sensor, made by Abbott. The Instinct sensor is small, thin, and worn discreetly, with up to 15 days of wear. This milestone expands sensor choice for Medicare users, who also have access to the Simplera Sync and Guardian 4 sensors. Access to advanced technologies like the MiniMed 780G system can help reduce burden by automating insulin delivery, responding to glucose changes every five minutes, and supporting more stable glucose control. This means fewer highs and lows, less daily decision-making, and a more streamlined way to stay within recommended glucose ranges.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MDT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MDT
Wall Street analysts forecast MDT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDT is 111.76 USD with a low forecast of 102.00 USD and a high forecast of 120.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
11 Buy
9 Hold
0 Sell
Moderate Buy
Current: 102.950
Low
102.00
Averages
111.76
High
120.00
Current: 102.950
Low
102.00
Averages
111.76
High
120.00
About MDT
Medtronic Public Limited Company is an Ireland-based company, which provides healthcare technology solutions. The Company’s products category includes Advanced Surgical Technology; Cardiac Rhythm; Cardiovascular; Digestive & Gastrointestinal; Ear, Nose & Throat; General Surgery; Gynecological; Neurological; Oral & Maxillofacial; Patient Monitoring; Renal Care; Respiratory; Spinal & Orthopedic; Surgical Navigation & Imaging; Urological; Product Manuals; Product Ordering & Inquiries; and Product Performance & Advisories. Its products include Cardiac Implantable Electronic Device (CIED) Stabilization, Aortic Stent Graft Products, CareLink Personal Therapy Management Software, CareLink Pro Therapy Management Software. Its services and solutions include Ambulatory Surgery Center Resources, Care Management Services, Digital Connectivity Information Technology (IT) Support, Equipment Services and Support, Innovation Lab, Medtronic Healthcare Consulting, and Office-Based Sinus Surgery.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly's Stock Rises Sharply Due to Increased Demand for GLP-1 Drugs
- Stock Performance: Eli Lilly's stock has surged 225% over the past three years, significantly outperforming the S&P 500's 66% gain, indicating strong performance in the GLP-1 drug market, although its high P/E ratio of 49 may deter some investors.
- Competitive Landscape: While Novo Nordisk ranks second in the GLP-1 drug market, its newly launched GLP-1 pill is seeing demand exceed expectations, potentially driving future growth, despite its stock being down 66% from 2024 highs.
- Medical Device Restructuring: Medtronic plans to spin off its diabetes business in 2026; although this division has been growing rapidly, its lower margins mean that the spinoff will enhance overall profitability and accelerate growth in its higher-margin sectors.
- Future Growth Potential: Despite Eli Lilly's strong performance in the GLP-1 market, Novo Nordisk's pill catalyst could help it regain momentum, while Medtronic's restructuring may unlock significant growth potential, making both companies worthy of investor attention.
See More
Eli Lilly's Stock Soars 225%, Attracting Attention
- Eli Lilly's Strong Performance: Eli Lilly's stock has surged 225% over the past three years, significantly outperforming the S&P 500's 66% gain, indicating robust market performance and investor confidence.
- Novo Nordisk's Market Challenge: Although Novo Nordisk was first to market with a GLP-1 weight-loss drug, Eli Lilly's offerings have been better received, resulting in a 66% drop in Novo Nordisk's stock from its 2024 highs, highlighting competitive pressures.
- Medtronic's Business Restructuring: Medtronic plans to spin off its diabetes business in 2026; despite rapid growth in this division, its lower margins compared to other operations suggest that the spinoff will enhance overall profitability and growth potential.
- Future Growth Potential: Eli Lilly's past success does not guarantee future dominance, as Novo Nordisk's GLP-1 pill could revitalize its sales, while Medtronic's restructuring may unlock higher growth opportunities.
See More
Eli Lilly's Stock Soars 225% Amid Market Dynamics
- Eli Lilly's Strong Performance: Eli Lilly's stock (NYSE: LLY) has surged 225% over the past three years, significantly outperforming the S&P 500's 66% gain, reflecting robust market performance and investor confidence.
- GLP-1 Market Competition: While Eli Lilly excels in the GLP-1 drug sector, competitor Novo Nordisk (NYSE: NVO) is also launching new GLP-1 medications, which are expected to attract more consumers and drive long-term market growth.
- Medtronic's Strategic Shift: Medtronic (NYSE: MDT) plans to spin off its diabetes division in 2026; although this segment has been growing rapidly, it has lower margins, and the spinoff is expected to enhance overall profitability and accelerate company growth.
- Future Outlook: Despite Eli Lilly's past successes, future market competition remains fierce, with Novo Nordisk's GLP-1 drugs and Medtronic's business restructuring potentially reshaping the industry landscape, prompting investors to carefully assess risks and opportunities.
See More
Market Turmoil and Corporate Earnings Analysis
- Tech Sector Weakness: S&P futures tumbled due to weakness in Big Tech, with Bitcoin falling below $70,000 for the first time, indicating intensified sell-off in the crypto market that could undermine investor confidence and exacerbate market volatility.
- Job Market Instability: Challenger, Gray & Christmas reported that planned layoffs at American companies hit the highest January total since the global financial crisis, with hiring intentions at their lowest, reflecting the fragility of economic recovery and potential decline in consumer spending.
- Alphabet Price Target Hikes: Following a strong quarterly report, Wall Street analysts raised Alphabet's price targets, yet shares fell over 5% in early trading due to market rotation away from tech, highlighting concerns about future growth amidst competitive pressures.
- Boston Scientific Stock Plunge: Boston Scientific shares sank 17.5% on Wednesday, marking its largest single-day decline in 25 years after disappointing quarterly earnings, although Citi maintained a buy rating, indicating that increased competition could impact its market share.
See More
Healthcare Stocks Show Dividend Growth Potential
- AbbVie's Dividend Performance: AbbVie boasts a dividend yield of 2.98% and has increased its quarterly dividend for 54 consecutive years, raising it by 5.5% to $1.73 per share in 2023, demonstrating strong cash flow and consistent dividend growth capability.
- Strong Financial Performance: AbbVie reported third-quarter revenue of $15.8 billion, a 9% year-over-year increase, although earnings per share fell 38% to $1.86, its investments in oncology are expected to lay the groundwork for future growth and enhance market competitiveness.
- Medtronic's Market Position: Medtronic, the largest stand-alone medical device maker with a market cap of $132 billion, reported second-quarter revenue of $9 billion, up 6.6% year-over-year, and forecasts a 5.5% revenue increase in 2026, indicating sustained growth potential in the medical device sector.
- Sustainability of Dividend Growth: With dividend payout ratios of 58% for AbbVie and 69% for Medtronic, both companies maintain relatively high ratios; however, due to strong free cash flow and ongoing revenue growth, they are expected to sustain their dividend payments, bolstering investor confidence.
See More
AbbVie and Medtronic's Dividend Growth Potential
- AbbVie Dividend Performance: AbbVie boasts a dividend yield of 2.98% and has increased its quarterly dividend for 54 consecutive years, raising it by 5.5% to $1.73 per share in 2023, demonstrating strong cash flow and sustainable dividend growth potential.
- Medtronic Market Growth: In Q2 of fiscal 2026, Medtronic reported $9 billion in revenue, a 6.6% year-over-year increase, with EPS rising 8% to $1.07, and it anticipates a 5.5% revenue growth, showcasing its successful pivot into smart devices.
- Importance of R&D Investment: Both companies prioritize R&D, with AbbVie investing over $19 billion in 2023 to ensure ongoing product innovation, while Medtronic focuses on new product development to maintain competitiveness despite dividend payout pressures.
- Market Competitive Advantage: The size and diversification of AbbVie and Medtronic allow them to sustain revenue growth across various market segments, with AbbVie's oncology products accounting for 11% of its revenue and Medtronic planning to spin off its diabetes business to optimize resource allocation.
See More
Eli Lilly's Stock Rises Sharply Due to Increased Demand for GLP-1 Drugs
- Stock Performance: Eli Lilly's stock has surged 225% over the past three years, significantly outperforming the S&P 500's 66% gain, indicating strong performance in the GLP-1 drug market, although its high P/E ratio of 49 may deter some investors.
- Competitive Landscape: While Novo Nordisk ranks second in the GLP-1 drug market, its newly launched GLP-1 pill is seeing demand exceed expectations, potentially driving future growth, despite its stock being down 66% from 2024 highs.
- Medical Device Restructuring: Medtronic plans to spin off its diabetes business in 2026; although this division has been growing rapidly, its lower margins mean that the spinoff will enhance overall profitability and accelerate growth in its higher-margin sectors.
- Future Growth Potential: Despite Eli Lilly's strong performance in the GLP-1 market, Novo Nordisk's pill catalyst could help it regain momentum, while Medtronic's restructuring may unlock significant growth potential, making both companies worthy of investor attention.
See More
Eli Lilly's Stock Soars 225%, Attracting Attention
- Eli Lilly's Strong Performance: Eli Lilly's stock has surged 225% over the past three years, significantly outperforming the S&P 500's 66% gain, indicating robust market performance and investor confidence.
- Novo Nordisk's Market Challenge: Although Novo Nordisk was first to market with a GLP-1 weight-loss drug, Eli Lilly's offerings have been better received, resulting in a 66% drop in Novo Nordisk's stock from its 2024 highs, highlighting competitive pressures.
- Medtronic's Business Restructuring: Medtronic plans to spin off its diabetes business in 2026; despite rapid growth in this division, its lower margins compared to other operations suggest that the spinoff will enhance overall profitability and growth potential.
- Future Growth Potential: Eli Lilly's past success does not guarantee future dominance, as Novo Nordisk's GLP-1 pill could revitalize its sales, while Medtronic's restructuring may unlock higher growth opportunities.
See More
Eli Lilly's Stock Soars 225% Amid Market Dynamics
- Eli Lilly's Strong Performance: Eli Lilly's stock (NYSE: LLY) has surged 225% over the past three years, significantly outperforming the S&P 500's 66% gain, reflecting robust market performance and investor confidence.
- GLP-1 Market Competition: While Eli Lilly excels in the GLP-1 drug sector, competitor Novo Nordisk (NYSE: NVO) is also launching new GLP-1 medications, which are expected to attract more consumers and drive long-term market growth.
- Medtronic's Strategic Shift: Medtronic (NYSE: MDT) plans to spin off its diabetes division in 2026; although this segment has been growing rapidly, it has lower margins, and the spinoff is expected to enhance overall profitability and accelerate company growth.
- Future Outlook: Despite Eli Lilly's past successes, future market competition remains fierce, with Novo Nordisk's GLP-1 drugs and Medtronic's business restructuring potentially reshaping the industry landscape, prompting investors to carefully assess risks and opportunities.
See More
Market Turmoil and Corporate Earnings Analysis
- Tech Sector Weakness: S&P futures tumbled due to weakness in Big Tech, with Bitcoin falling below $70,000 for the first time, indicating intensified sell-off in the crypto market that could undermine investor confidence and exacerbate market volatility.
- Job Market Instability: Challenger, Gray & Christmas reported that planned layoffs at American companies hit the highest January total since the global financial crisis, with hiring intentions at their lowest, reflecting the fragility of economic recovery and potential decline in consumer spending.
- Alphabet Price Target Hikes: Following a strong quarterly report, Wall Street analysts raised Alphabet's price targets, yet shares fell over 5% in early trading due to market rotation away from tech, highlighting concerns about future growth amidst competitive pressures.
- Boston Scientific Stock Plunge: Boston Scientific shares sank 17.5% on Wednesday, marking its largest single-day decline in 25 years after disappointing quarterly earnings, although Citi maintained a buy rating, indicating that increased competition could impact its market share.
See More
Healthcare Stocks Show Dividend Growth Potential
- AbbVie's Dividend Performance: AbbVie boasts a dividend yield of 2.98% and has increased its quarterly dividend for 54 consecutive years, raising it by 5.5% to $1.73 per share in 2023, demonstrating strong cash flow and consistent dividend growth capability.
- Strong Financial Performance: AbbVie reported third-quarter revenue of $15.8 billion, a 9% year-over-year increase, although earnings per share fell 38% to $1.86, its investments in oncology are expected to lay the groundwork for future growth and enhance market competitiveness.
- Medtronic's Market Position: Medtronic, the largest stand-alone medical device maker with a market cap of $132 billion, reported second-quarter revenue of $9 billion, up 6.6% year-over-year, and forecasts a 5.5% revenue increase in 2026, indicating sustained growth potential in the medical device sector.
- Sustainability of Dividend Growth: With dividend payout ratios of 58% for AbbVie and 69% for Medtronic, both companies maintain relatively high ratios; however, due to strong free cash flow and ongoing revenue growth, they are expected to sustain their dividend payments, bolstering investor confidence.
See More
AbbVie and Medtronic's Dividend Growth Potential
- AbbVie Dividend Performance: AbbVie boasts a dividend yield of 2.98% and has increased its quarterly dividend for 54 consecutive years, raising it by 5.5% to $1.73 per share in 2023, demonstrating strong cash flow and sustainable dividend growth potential.
- Medtronic Market Growth: In Q2 of fiscal 2026, Medtronic reported $9 billion in revenue, a 6.6% year-over-year increase, with EPS rising 8% to $1.07, and it anticipates a 5.5% revenue growth, showcasing its successful pivot into smart devices.
- Importance of R&D Investment: Both companies prioritize R&D, with AbbVie investing over $19 billion in 2023 to ensure ongoing product innovation, while Medtronic focuses on new product development to maintain competitiveness despite dividend payout pressures.
- Market Competitive Advantage: The size and diversification of AbbVie and Medtronic allow them to sustain revenue growth across various market segments, with AbbVie's oncology products accounting for 11% of its revenue and Medtronic planning to spin off its diabetes business to optimize resource allocation.
See More
